Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022
Relmada Therapeutics (Nasdaq: RLMD) announced it will disclose its financial results for Q4 and the full year ended December 31, 2021, after market close on March 23, 2022. A corporate update conference call and live audio webcast is scheduled for 4:30 PM ET on the same date. Relmada focuses on central nervous system diseases, particularly major depressive disorder (MDD), and is advancing its lead program, REL-1017, which has shown promising results in clinical trials as a treatment for MDD.
- REL-1017 demonstrated robust, rapid, and sustained antidepressant effects in a Phase 2 trial.
- Positive pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with earlier Phase 1 studies.
- None.
CORAL GABLES, Fla., March 16, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market close on Wednesday, March 23, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Wednesday, March 23, 2022.
Live Conference Call & Webcast: | |
Toll Free: | 877-407-0792 |
International: | 201-689-8263 |
Conference ID: | 13727905 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1536859&tp_key=0d9f65e796 |
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated robust, rapid, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com
Media Inquiries:
FischTank PR
Relmada@FischTankPR.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conference-call-and-webcast-on-march-23-2022-301504032.html
SOURCE Relmada Therapeutics, Inc.
FAQ
When will Relmada Therapeutics report its Q4 2021 financial results?
What is the focus of Relmada Therapeutics?
What is REL-1017?
